Adjuvant Hormonal Therapy for Premenopausal Women with Breast Cancer
Overview
Authors
Affiliations
Endocrine therapy is a required element of the management of premenopausal women with early-stage steroid hormone receptor-positive breast cancer. There is uncertainty about how best to implement that therapy using the strategies of tamoxifen and estrogen deprivation as well as how to integrate these approaches with chemotherapy. Other research focuses on identification of improved markers for endocrine response or resistance and on the special side effects of endocrine therapy in young women.
LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1.
Yuan H, Zhou L, Hu W, Yang M Sci Rep. 2025; 15(1):2997.
PMID: 39848992 PMC: 11757752. DOI: 10.1038/s41598-025-86287-2.
ERα is a target for butein-induced growth suppression in breast cancer.
Huang C, Xia X, He J, Liu Y, Shao Z, Hu T Am J Cancer Res. 2020; 10(11):3721-3736.
PMID: 33294263 PMC: 7716169.
Xia X, He J, Liu B, Shao Z, Xu Q, Hu T Int J Biol Sci. 2020; 16(12):2192-2204.
PMID: 32549765 PMC: 7294940. DOI: 10.7150/ijbs.44005.
The Widening Sphere of Influence of HOXB7 in Solid Tumors.
Errico M, Jin K, Sukumar S, Care A Cancer Res. 2016; 76(10):2857-62.
PMID: 27197229 PMC: 4874556. DOI: 10.1158/0008-5472.CAN-15-3444.
A pivotal role for HOXB7 protein in endocrine resistant breast cancer.
Jin K, Sukumar S Oncoscience. 2015; 2(11):917-9.
PMID: 26697525 PMC: 4675788. DOI: 10.18632/oncoscience.263.